RXi Pharmaceuticals Corporation (NASDAQ:RXII) announced that it will report financial results for the second quarter ended June 30, 2015 on Wednesday, August 12, 2015 after the close of the U.S. financial markets. RXi Pharmaceuticals Corporation (NASDAQ:RXII) belongs to Healthcare sector. Its weekly performance is -8.42%. On last trading day company shares ended up $0.41. RXi Pharmaceuticals Corporation (NASDAQ:RXII) distance from 50-day simple moving average (SMA50) is -11.77%.
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) announced that it plans to issue a press release reporting its 2015 second quarter and operational update after the close of the market on Monday, August 10, 2015. Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) shares increased 2.68% in last trading session and ended the day at $10.71. ANTH return on assets is -133.60%. Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) quarterly performance is 142.86%.
Solera Holdings Inc. (NYSE:SLH) announced it has acquired Autodata B.V. (“Autodata”), a leading provider of vehicle valuation, inventory management and workflow software for automotive dealers and leasing companies in the Netherlands. Autodata’s fully integrated suite of vehicle valuation, inventory management and marketing services provides data on approximately one in every four pre-owned cars for sale in the Dutch marketplace. In addition to enhancing its customer value proposition, Solera plans to leverage Autodata’s proprietary data to establish a standardized vehicle valuation methodology across Europe. Autodata’s solutions will also be integrated with Solera’s risk and asset management solutions that bring together property insurers, auto dealers, vehicle mechanics, car manufacturers and consumers into one digital marketplace. On 04 August, Solera Holdings Inc. (NYSE:SLH) shares increased 4.70% and was closed at $38.10. SLH EPS growth in last 5 year was -16.60%. Solera Holdings Inc. (NYSE:SLH) year to date (YTD) performance is -25.00%.
Automated-teller machine maker NCR Corp. (NCR) said that the U.S. Securities and Exchange Commission notified the Company that it did not intend to recommend an enforcement action against the Company over 2012 allegations of foreign bribery violations. The company responded to its most recent requests for documents in 2014. On June 22, 2015, the SEC staff notified the Company that it did not intend to recommend an enforcement action against the Company with respect to these matters, the company disclosed in July 31 regulatory filing.
Pfizer Inc. (NYSE:PFE) announced that the European Commission has approved the company’s pending acquisition of Hospira Inc. (HSP). The approval is conditional on Pfizer divesting certain sterile injectable drugs, as well as its infliximab biosimilar drug, which is currently under development. In early February, Pfizer agreed to acquire Hospira for $15.23 billion in cash to improve the growth trajectory of its global established pharmaceutical business. Pfizer Inc. (NYSE:PFE) shares decreased -0.11% in last trading session and ended the day at $36.11. PFE Gross Margin is 81.30% and its return on assets is 5.30%. Pfizer Inc. (NYSE:PFE) quarterly performance is 6.71%.